It seems that despite the efforts of many manufacturers to reduce the potential harm of their products -smokeless or otherwise - there needs to be a regulatory framework in place (in every country where tobacco is used) to assess any claims about reduced harm made by a manufacturer about their product(s).
Without such a framework in place, how can tobacco manufacturers market these reduced harm products without the danger of litigation against them being preclusive to marketing them as such?
Will your research and findings be presented to any governmental bodies to offer insight into a possible framework or criteria for defining a reduced harm product?
I understand the concern that manufacturers might not feel at liberty to make reduced-harm claims, even when they are clearly true. Some people claim they can, but I understand why they are hesitant --I even had a brief debate about this when trying to get a paper published (http://www.biomedcentral.com/1471-2458/5/31/prepub, Author's comments for Resubmission Version 2). It would be great if regulations explicitly said that truthful claims are allowed, and companies probably will fear saying anything without that (which I find unfortunate, but not at all surprising). Unfortunately, new regulations could make things worse rather than better. Several harm-reduction advocates (Bill Godshall in particular) lobbied against a recent bill in the U.S. legislature that ostensibly regulated tobacco in the public interest, because they felt that it did more to protect the market for big cigarette companies than anything else. In particular, it would have actually prevented tobacco companies from making comparative risk claims.
Most of us involved with harm reduction have presented results to governmental bodies. The European Union, where moist snuff is actually banned outside of Sweden (but cigarettes are allowed and quite popular), is currently considering changing their policy to allow the reduced-harm alternative onto the market, and many of us provided them with our work.
Carl V. Phillips, Associate Professor, University of Alberta School of Public Health